Clinical outcomes, management, and treatment patterns in patients with metastatic castration‐resistant prostate cancer treated with radium‐223 in community compared to academic settings. Issue 10 (12th May 2021)

• Record Type: Journal Article
• Authors: Sartor, Oliver; Appukkuttan, Sreevalsa; Weiss, Jeffrey; Tsao, Che‐Kai
• Is Part Of: Prostate. Volume 81:Issue 10(2021)
• Page Start: 657
• Page End: 666
• Publication Date: 2021-05-12
• Subjects: bone metastases -- castration resistance -- prostate cancer -- radium‐223 -- real‐world data; Prostate -- Diseases -- Periodicals; 616
• DOI: 10.1002/pros.24143
• Languages: English
• ISSNs: 0270-4137

Abstract

Abstract: Background: The most common site of disease in metastatic castration‐resistant prostate cancer (mCRPC) is the bone. The ALSYMPCA study demonstrated that radium‐223 significantly improved overall survival (OS) in mCRPC patients with symptomatic bone metastases and without visceral metastases. However, administration requires a multidisciplinary approach and an infrastructure that supports coordination of care, which may differ by practice site. We aimed to evaluate practice patterns and treatment outcomes in patients with mCRPC treated at a community practice (CP) compared with those treated at an academic center (AC). Methods: This retrospective review included 200 adult mCRPC patients receiving radium‐223 between January 2014 and June 2017. The primary endpoint, OS, was estimated from the date of radium‐223 initiation. Secondary outcomes included a comparison of baseline characteristics, reasons for initiation and discontinuation of radium‐223, and treatment sequencing. A subset analysis of OS based on the number of radium‐223 doses and on sequencing of radium‐223 either before or after chemotherapy was also conducted. Results: Most patients were treated at a CP (57%). Patients treated at CP sites were significantly older (74.9 vs. 71.9 years; p = .031) and had more comorbidities (Klabunde score 1.1 vs. 0.7; p = .020) than those in an AC but initiated treatment within a shorter period of time from diagnosis of mCRPC (1.3 vs. 1.9 years; p < .001) and received a greater mean number of radium‐223 doses (5.4 vs. 4.8; p = .001). There were no observed differences in OS between CPs versus ACs (21.6 vs. 20.7 months; p = .306). Overall, patients who received 5–6 doses versus 1–4 doses of radium‐223 had a longer median OS (23.3 vs. 6.4 months; p < .001). The most common reason for discontinuation in patients who did not complete treatment was disease progression. Overall, 43% of patients received radium‐223 monotherapy and 57% concurrently with other agents. Conclusions: Most patients received radium‐223 concurrently with abiraterone acetate or enzalutamide and were able to complete 5–6 doses of radium‐223. Despite differences in the populations and treatment patterns, no survival differences between patients treated in ACs versus CPs were observed. Additional real‐world data are needed to validate these findings.